Articles tagged with Antidepressants
A new study published in JAMA Internal Medicine found that strong anticholinergic medication daily for three years or more may increase the risk of dementia by nearly 50% among patients aged 55 and over. The research highlights the importance of carefully considering medication risks alongside benefits.
Researchers found that antidepressant treatment, rather than depression itself, leads to reduced neural responses and empathy towards pain in patients. This effect may help patients recover from social interactions more easily.
A systematic review found that serotonin and norepinephrine reuptake inhibitors (SNRIs) led to more harmful events compared to placebos in older adults. Antidepressants like SSRIs may increase the risk of falls, highlighting the need for careful consideration when prescribing these medications.
A study found that patients taking antihypertensive drugs had a decreased risk of developing dementia, with calcium channel blockers showing the most significant association. The study analyzed data from over 12,000 patients and suggested that these medications may help delay or reduce dementia onset.
A Japanese study found that cognitive therapy maintained its effects more than a year after therapy for patients with social anxiety disorder (SAD) who did not respond to antidepressant drugs. Cognitive therapy helped patients overcome negative thoughts and behaviors, allowing them to enjoy social interactions more.
A research team at DGIST discovered that changes in hippo campal mossy cells play a crucial role in the treatment efficacy of serotoninergic antidepressants. This finding contributes to the development of next-generation antidepressants with enhanced effects and speed.
Researchers at University of Malaga identify a fragment of the brain molecule Galanin as involved in anhedonia, a key symptom of depression. The study suggests potential new therapeutic strategies for treating depression and related addictions.
A new study published in the American Journal of Psychiatry supports the effectiveness and safety of esketamine nasal spray for treating moderate to severe depression in people who have not responded to previous treatment. The study found significant improvements in depression symptoms within 24 hours of taking the medication.
Researchers have found that smokers with COPD have significant unmet mental health care needs, particularly anxiety and depressive symptoms. These symptoms can impact many COPD-related outcomes, including hospital readmissions and exacerbations.
A study found a potential link between autistic-like behaviour in adult mice and exposure to fluoxetine, a common antidepressant, in the womb. The researchers identified a treatment that improved memory loss and social interactions.
Scientists have discovered the three major shapes of the serotonin transporter using cryo-EM technology. The study provides new avenues for developing medications to treat addiction without hallucinogenic properties.
Researchers found that ketamine restores dendritic spines in the prefrontal cortex of mice with depression-like behavior. Healthy dendritic spines are crucial for long-term antidepressant effects, suggesting interventions to enhance their survival may be helpful in sustaining ketamine's benefits.
A meta-analysis of international studies found that anti-inflammatory medicine can have a beneficial effect on symptoms of depression. Six different medications showed an antidepressant effect, and the results were present when compared to a placebo in patients with physical diseases and depressive symptoms.
Rapastinel, an antidepressant-turned-opioid-reversal-drug, has shown promising results in reducing withdrawal signs in rats, potentially leading to a new treatment option for opioid dependence. The drug binds to the same receptor as ketamine but with a milder effect, offering a safer alternative to existing treatments.
Researchers identified discrepancies in 363 reports (15%) of adverse drug reactions between men and women. Drugs like thyroid hormones and antidepressants showed higher frequencies among female patients.
Researchers at UMSOM have discovered a crucial receptor called mGlu2 that is critical to the mechanism of fast-acting antidepressants like ketamine. The discovery could lead to better treatments for depression by understanding how the brain reacts to Ketamine.
A new 12-year longitudinal study found that consistent treatment with methylphenidate-based medications during childhood increases the risk of antidepressant use during adolescence. Children with high adherence (above 50%) were at significantly greater risk of being prescribed antidepressants between the ages of 12-18.
A research collaboration between Columbia University and a genomicist has identified specific genetic pathways associated with antidepressant resistance. The team hopes to develop new treatments that can circumvent resistance in millions of people who do not respond to current medications.
Researchers at CAMH have discovered a new target for developing treatments for depression by finding higher levels of the brain protein MAO-B in people with clinical depression. The study found that individuals with depression had 26% higher MAO-B levels in their prefrontal cortex compared to those without depression.
A new study published in JAMA Psychiatry found that combining antidepressants with antipsychotic drugs may have benefits for individuals with schizophrenia. The research suggests that antidepressant use can reduce the risk of hospitalization by 16% compared to antipsychotics and by 22% compared to benzodiazepines.
A study published by University of Sydney found a significant increase in self-poisonings among young Australians aged 5-19 years from 2006 to 2016. The incidence rose by 98% and was predominantly caused by substances widely available, such as household products and prescribed medications.
A study from the University of Virginia Health System suggests that an antidepressant drug could stop deadly sepsis by regulating inflammation. The researchers tested the drug in a mouse model and found it to be effective, paving the way for potential human trials.
A Stanford University School of Medicine investigation discovered that common opioids are less effective for patients taking selective serotonin reuptake inhibitors (SSRIs) for depression. This interaction may lead to reduced pain relief and increased risk of opioid abuse.
A large UK population-based study found no association between the antidepressant trazodone and a reduced risk of dementia. Researchers analyzed data from over 15 million patients and compared them with users of other antidepressants, but found higher incidence rates among trazodone users.
A comprehensive analysis of medications prescribed for children and adolescents with anxiety disorders found SSRIs to be the most effective and best-tolerated treatment. The study examined over a dozen medications from 22 randomized controlled trials, providing guidance for clinicians in selecting evidence-based medication treatments.
A study by Yale researchers reveals a complex interplay between brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) in the rapid and long-lasting antidepressant effects of ketamine. Administering BDNF or VEGF to specific brain regions produces rapid and long-lasting antidepressant-like actions similar...
Patients on SSRIs are 40% more likely to develop severe GI bleeding when taking NSAIDs, according to a review in the Journal of the American Osteopathic Association. Physicians should educate patients on recognizing symptoms and monitor for bleeding risks during SSRI therapy.
A study of elderly residents in Olmsted County, Minnesota found nearly one-quarter were overprescribed antidepressant medications. Patients with multiple comorbidities and high clinical complexity were at highest risk.
A study published in the Harvard Review of Psychiatry found that antidepressants may affect fertility in women, but the evidence is limited. In contrast, the impact on male fertility is unclear and requires further research.
A Swedish study found a significant correlation between dementia and ischemic stroke, with patients dying from IS having a higher mortality rate compared to those who did not have IS. The study also highlights the importance of accurate death certificate diagnoses, particularly for deaths reported outside Swedish hospitals.
Researchers have reviewed recent developments in monoamine transporter inhibitor design, including structure-activity relationships and binding modes. The study highlights potential applications for these inhibitors in treating depression and behavioral disorders.
Administration of fluoxetine to zebrafish embryos reduced cortisol levels in three subsequent generations, affecting gene expression and steroid production pathways. The antidepressant's impact on offspring was more pronounced in males than females.
A recent study published in The Lancet found that fluoxetine, a common antidepressant, does not improve physical ability or reduce disability after stroke. However, researchers did note a small increase in bone fractures among those taking the medication.
A recent study using marmosets identified the brain region responsible for anhedonia, a key symptom of depression. The researchers found that over-activity in this region blunts excitement and motivation, but a commonly used antidepressant ketamine blocks these effects, suggesting new treatment possibilities.
Researchers found that antidepressant prescriptions rose by 13.4% after the Brexit vote, potentially due to increased uncertainty among some populations. Strengthening mental health service provision during such periods is advised.
A nationwide Danish study found that depressed individuals have a higher risk of developing atrial fibrillation. The study also revealed that antidepressant medication itself is not associated with the development of atrial fibrillation, contradicting previous concerns.
A study suggests that pharmacogenetic tests don't provide significant benefits in selecting antidepressant or antipsychotic medications. Instead, understanding drug metabolism can predict which drugs are likely to work well for individual patients.
A new study found that legacy prescribing patterns are widespread, with 46% of patients prescribed antidepressants continuously for more than 15 months. The researchers highlight the need for system-oriented change to address this issue and explore legacy prescribing as a quality measure.
Researchers found that ezogabine, an FDA-approved anti-seizure medication, significantly reduced depressive symptoms in patients with Major Depressive Disorder. The study showed a 45% reduction in depression and improved resilience after treatment.
A large-scale study found no strong associations between prenatal exposure to certain medications and increased autism spectrum disorder (ASD) risk. However, the risk was higher for children whose mothers had pre-existing conditions, suggesting a potential link between maternal health and ASD development.
A combination of buprenorphine and samidorphan has shown significant symptom reduction in patients with major depression, with no evidence of dependence or withdrawal. The trials suggest a new class of antidepressants with a novel mechanism of action could have a significant impact for patients with persistent symptoms.
A multiyear clinical trial found that patients who chose their form of treatment, whether medication or therapy, improved more than those who were simply prescribed one or the other. Patients who received prolonged exposure therapy showed a significant reduction in PTSD symptoms and were more likely to lose their diagnosis over time.
Supervised aerobic exercise demonstrated large antidepressant effects in patients with major depression, significantly better than medication and/or psychological therapies. It showed comparable effects across various settings and delivery formats, including outpatient and inpatient care.
A systematic review found that serotonin-noradrenaline reuptake inhibitors can cause withdrawal symptoms when discontinued, with venlafaxine showing higher prevalence rates. These symptoms typically occur within a few days of stopping the medication and can last several weeks.
Researchers found that a single dose of cannabidiol eliminated symptoms of depression in rats and maintained benefits for up to seven days. The study's findings suggest that cannabidiol rapidly triggers neuroplastic mechanisms to repair damaged neuronal circuitry, providing new hope for treating broad-spectrum depression.
A new study found that ketamine's antidepressant effect requires opioid system activation in humans, raising concerns about the risk of dependence. The study used naltrexone, an opioid blocker, to block ketamine's effects and found that it reduced antidepressant symptoms but not dissociative effects.
Stanford researchers found that ketamine works as an antidepressant by activating the brain's opioid system. The study overturns previous beliefs about the drug's mechanism and presents new treatment opportunities for depression, pain, and opioid addiction.
A study found that nearly 20% of children use prescription medications, with 7.5% using multiple medications simultaneously. Adolescent girls are most vulnerable to harmful drug-drug interactions due to higher concurrent use of antidepressants and other psychotropic medications.
A recent study found that vagus nerve stimulation significantly improves quality-of-life measures in treatment-resistant depression patients. The therapy shows promise for individuals who don't respond to traditional antidepressants or experience only partial improvement.
A new review suggests that mitochondrial dysfunction may be the root cause of depression, providing a potential breakthrough for novel antidepressant medication. The researchers found that depression is associated with decreased energy production and increased metabolic demand in brain cells.
Researchers developed an AI algorithm that analyzes brain scans to classify illness and predict medication response in patients with complex mood disorders. The algorithm correctly classified MDD and bipolar I diagnoses with 92.4% accuracy, predicting the correct medication response for 11 out of 12 patients.
Next-generation metabolomics may facilitate the discovery of new antidepressants by providing broader coverage and higher resolution than traditional methods. The technique has demonstrated great potential in accelerating pharmaceutical R&D, particularly for natural products like albiflorin, a promising multi-target drug candidate.
A new study by the University of York found that dilute concentrations of Prozac make female starlings less attractive to males during courtship. The researchers discovered increased male aggression towards females receiving the medication, leading to a higher risk of mate failure and population decline.
Individuals with MDD have lower LAC levels than healthy controls, increasing with disease severity and age of onset. Patients with low LAC levels often do not respond to standard antidepressant medications, suggesting LAC may aid in diagnosing severe, trauma-associated depression.
A randomized clinical trial of 300 patients in South Korea found that antidepressant escitalopram reduced major adverse cardiac events by 13% compared to placebo. The study followed patients for about eight years, revealing a lower occurrence of cardiac events among those receiving antidepressant treatment.
A new review of published observational studies reveals that depression and the use of antidepressants are both associated with an increased risk of VTE. The study's findings suggest that prescribers and healthcare professionals should evaluate patients to determine their excess risk of VTE during management.
Researchers have developed an algorithm that predicts which individuals with depression are most likely to benefit from antidepressant medications. The study found that approximately one-third of participants responded meaningfully to medication, while the remaining two-thirds showed no significant improvement.
Researchers at UCalgary have discovered that the antidepressant mirtazapine may be an effective treatment for PBC, a rare and incurable liver disease. The study found that patients taking mirtazapine showed improved health outcomes compared to those without depression.
A new study finds that antidepressant use in people with chronic obstructive pulmonary disease (COPD) is associated with a 20% increase in likelihood of death and a 15% increase in hospitalization due to respiratory-related symptoms. The study suggests strong association, but not cause and effect.
Researchers found ketamine's rapid antidepressant effect is linked to the fast release of G proteins from membrane patches. This allows for better communication among brain cells, alleviating depressive symptoms. The long-lasting effects may be due to slow G protein re-entry into lipid rafts.